{"id":41662,"date":"2026-02-23T14:09:36","date_gmt":"2026-02-23T14:09:36","guid":{"rendered":"https:\/\/allonlinebanglanewspapers.com\/news\/nucleus-upgrades-preview-the-first-true-glimpse-of-your-future-child\/"},"modified":"2026-02-23T14:09:36","modified_gmt":"2026-02-23T14:09:36","slug":"nucleus-upgrades-preview-the-first-true-glimpse-of-your-future-child","status":"publish","type":"post","link":"https:\/\/allonlinebanglanewspapers.com\/news\/nucleus-upgrades-preview-the-first-true-glimpse-of-your-future-child\/","title":{"rendered":"Nucleus Upgrades Preview, The First True Glimpse of Your Future Child"},"content":{"rendered":"
\n

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) — Nucleus Genomics<\/u><\/a> today introduced Preview<\/u><\/strong><\/a>, a new approach to carrier screening that expands what couples can learn before conception.<\/p>\n

By combining rare and chronic disease screening with trait modeling, Preview delivers a comprehensive genetic view of your future child, from cancer risk and heart disease to eye color and IQ \u2014 all from a cheek swab.<\/p>\n

Traditional Carrier Screening Falls Short
<\/strong>For more than 50 years, carrier screening has asked a narrow question: are both parents carriers of the same rare mutation?<\/p>\n

But it misses the fact that the majority of genetic risk doesn\u2019t come from a single gene<\/u><\/a>. The conditions that shape most lives, from heart disease and diabetes to cancers, Alzheimer’s and hypertension, arise from many genes acting together \u2014 something traditional screening doesn\u2019t capture.<\/p>\n

Preview, a Full View of Genetic Risk
<\/strong>Building on Nucleus Family<\/u><\/a>, introduced last year, Preview is a more advanced preconception experience and a redefinition of what carrier screening is. What began as one of the most expansive rare disease screenings now integrates polygenic risk and trait modeling.<\/p>\n

From a cheek swab, couples can see their child\u2019s risk across more than 2,000 rare inherited conditions alongside common diseases such as breast cancer, heart disease, type 2 diabetes, and hypertension. Preview extends this even further, modeling traits including eye color, height, and IQ.<\/p>\n

\u201cWill they inherit the disease that runs in the family? How tall will they be? Will they get my eyes? Every couple wonders about this when they’re having a child,\u201d said Kian Sadeghi, founder and CEO of Nucleus. \u201cUntil now, those answers remained elusive. Preview brings your future baby into view before conception.\u201d<\/p>\n

At the center of Preview is also a first-of-its-kind approach built on a simple truth: no two siblings inherit DNA the same way. Instead of estimating risk for a single hypothetical child, Preview shows how disease risk and traits distribute across up to 100 potential children. This is presented as a range rather than a single score, allowing parents to understand risk meaningfully.<\/p>\n

<\/p>\n

Preview offers preconception insight into common conditions like breast cancer, heart disease, type 2 diabetes, and hypertension, alongside traits like eye color, height, and IQ.<\/sup><\/em><\/p>\n

Why This Matters
<\/strong>Starting a family has long meant accepting uncertainty. Although the American College of Obstetricians and Gynecologists recommends carrier screening for all couples before pregnancy<\/u><\/a>, most families still conceive without any meaningful genetic screening.<\/p>\n

Preview changes that, moving carrier screening from a rare clinical offering to an accessible consumer-initiated decision. For many, that brings confidence in natural conception; for others, it clarifies when IVF or additional care may matter, with a seamless path forward through Nucleus available.<\/p>\n

Couples can now plan for longevity and generational health before conception.<\/p>\n

Looking Ahead
<\/strong>The launch of Preview follows the rapid expansion of Nucleus\u2019 IVF+ clinic network<\/u><\/a>, including a recent partnership with Neway Fertility<\/u><\/a>. It also builds on the company\u2019s Have Your Best Baby<\/u><\/em> campaign<\/u><\/a>, which sought to broaden public understanding of the reproductive choices now available to families.<\/p>\n

Together, these efforts reflect a larger shift in family planning. Nucleus now spans preconception testing with Preview<\/u><\/a>, advanced embryo analysis through Embryo<\/u><\/a>, and an end-to-end fertility care experience with IVF+<\/u><\/a>.<\/p>\n

Preview is available today at mynucleus.com\/preview<\/u><\/strong><\/a>.<\/p>\n

Press contact <\/strong>
press@mynucleus.com<\/p>\n

About Nucleus Genomics
<\/strong>Nucleus Genomics<\/u><\/a> helps couples plan and have a baby. Its products span advanced carrier screening, embryo analysis, and an integrated IVF care experience, with a focus on building generational health. Nucleus has raised more than $32 million to date with investors including Founders Fund and Seven Seven Six. To learn more about Nucleus, visit https:\/\/mynucleus.com\/<\/u><\/a>.<\/p>\n

A photo accompanying this announcement is available at https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/3267c51f-5481-4ddb-93ed-4c3577203fad<\/a><\/p>\n

\"\"\n <\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) — Nucleus Genomics today introduced Preview, a new approach to carrier screening that expands what couples can learn before conception. By combining rare and chronic disease screening with trait modeling, Preview delivers a comprehensive genetic view of your future child, from cancer risk and heart disease to eye […]<\/p>\n","protected":false},"author":2,"featured_media":41663,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/8815da0e-8947-4709-8064-6b033ee4c530","fifu_image_alt":"","footnotes":""},"categories":[11],"tags":[],"class_list":["post-41662","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t